Frequency of Acute Otitis Media in Children Under 24 Months of Age Before and After the Introduction of the 10-valent Pneumococcal Conjugate Vaccine Into the National Immunization Program in Chile

被引:7
|
作者
Rosenblut, Andres [1 ]
Rosenblut, Macarena [2 ]
Garcia, Karen [3 ]
Maul, Ximena [4 ]
Santolaya, Maria E. [5 ]
机构
[1] Pontificia Univ Catolica Chile, Hosp Dr Sotero del Rio, Otorhinolaringol Serv, Huasos 1948, Santiago, Chile
[2] Univ Chile, Fac Med, Santiago, Chile
[3] Pontificia Univ Catolica Chile, Fac Med, Santiago, Chile
[4] Pontificia Univ Catolica Chile, Santiago, Chile
[5] Univ Chile, Fac Med, Dept Pediat, Hosp Dr Luis Calvo Mackenna, Santiago, Chile
关键词
acute otitis media; pneumococcal vaccine; pediatrics; NONTYPABLE HAEMOPHILUS-INFLUENZAE; PROTEIN-D; PHID-CV; STREPTOCOCCUS-PNEUMONIAE; IMMUNOGENICITY; SAFETY; REACTOGENICITY;
D O I
10.1097/INF.0000000000001722
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background:Streptococcus pneumoniae is the leading cause of acute otitis media (AOM). Ten-valent pneumococcal conjugated vaccine (PCV-10) was introduced to the Chilean National Immunization Program (NIP) in 2011. The aim of this study was to estimate the frequency of AOM in children <24 months of age attending the emergency department (ED) of Hospital Sotero del Rio (HSR) 4 years before and 4 years after the introduction of PCV-10 in the Chilean NIP. Methods: Register-based nested case-control study. Cases (n = 1907) were all children <24 months of age with a clinical diagnosis discharge of AOM at the ED of HSR, and controls (n = 244,334) were all other children <24 months of age attended at the same ED in the same time period, with any other discharge diagnosis. The data were obtained through HSR Statistical Service. Results: In the study period, there was a mean of 30,695 children <24 months managed each year at the ED of HSR. The percentage with AOM in the prevaccine period was 0.94% and in the postvaccine period was 0.62%, respectively (P = 0.026). Exposure to the PCV-10 was associated with a decreased risk to develop AOM in children <24 months, with an odds ratio of 0.659 (95% confidence interval: 0.60-0.72). Conclusions: Our study showed a significant decrease in the percentage and risk of AOM in children <24 months of age who visited the ED of HSR after implementation of PCV-10 in the NIP in Chile.
引用
收藏
页码:132 / 134
页数:3
相关论文
共 50 条
  • [1] Incidence of admissions due to pneumonia in children under 24 months old before and after the introduction of the 10-valent pneumococcal conjugate vaccine into the National Immunization Program of Chile
    Fernandez, Jose Pablo, V
    Goecke H, Carola
    von Borries, Cecilia
    Tapia R, Natalia
    Santolaya de P, Maria Elena
    REVISTA CHILENA DE PEDIATRIA-CHILE, 2015, 86 (03): : 168 - 172
  • [2] Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
    Richter, Lukas
    Schmid, Daniela
    Kanitz, Elisabeth Eva
    Zwazl, Ines
    Poellabauer, Eva
    Jasinska, Joanna
    Burgmann, Heinz
    Kundi, Michael
    Wiedermann, Ursula
    PLOS ONE, 2019, 14 (01):
  • [3] Pneumococcal meningitis before the introduction of 10-valent pneumococcal conjugate vaccine into the National Childhood Immunization Program in Poland
    Polkowska, Aleksandra
    Skoczynska, Anna
    Paradowska-Stankiewicz, Iwona
    Stefanoff, Pawel
    Hryniewicz, Waleria
    Kuch, Alicja
    Lyytikainen, Outi
    Nuorti, J. Pekka
    VACCINE, 2019, 37 (10) : 1365 - 1373
  • [4] Bacterial Spectrum of Acute Otitis Media in Bulgarian Children during the 10-Valent Pneumococcal Conjugate Vaccine Era
    Setchanova, Lena
    Stancheva, Iglika
    Popova, Diana
    Alexandrova, Alexandra
    Mitov, Ivan
    JOURNAL OF PEDIATRIC INFECTIOUS DISEASES, 2020, 15 (03) : 135 - 143
  • [5] Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program (vol 14, e0210081, 2019)
    Richter, Lukas
    Schmid, Daniela
    Kanitz, Elisabeth Eva
    Zwazl, Ines
    Pollabauer, Eva
    Jasinska, Joanna
    Burgmann, Heinz
    Kundi, Michael
    Wiedermann, Ursula
    PLOS ONE, 2019, 14 (02):
  • [6] Impact of 10-valent pneumococcal conjugate vaccine on the epidemiology of otitis media with otorrhea among Bangladeshi children
    Naziat, Hakka
    Rahman, Md Hafizur
    Das, Rajib C.
    Islam, Maksuda
    Saha, Shampa
    Hussain, Md. Manzoor
    Sattar, Asif
    Uddin, Mohammad J.
    Alam, Md Jahangir
    Whitney, Cynthia G.
    Saha, Senjuti
    Hooda, Yogesh
    Saha, Samir K.
    VACCINE, 2025, 55
  • [7] Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
    Kim, Hye-Young
    Park, Seong-Beom
    Kang, Eun-Sil
    Lee, Sang-Min
    Kim, Hyun-Jin
    Wasserman, Matt
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 909 - 918
  • [8] Characterization of acute otitis media otopathogens before the introduction of the pneumococcal conjugated vaccine into the national immunization program in Poland
    Kot, Aneta Gorska
    Greenberg, David
    Gastol, Karolina
    Zielinski, Adam
    Givon-Lavi, Noga
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2019, 127
  • [9] Etiology and Antimicrobial Susceptibility of Middle Ear Fluid Pathogens in Costa Rican Children With Otitis Media Before and After the Introduction of the 7-Valent Pneumococcal Conjugate Vaccine in the National Immunization Program
    Abdelnour, Arturo
    Arguedas, Adriano
    Dagan, Ron
    Soley, Carolina
    Porat, Nurith
    Castrejon, Maria Mercedes
    Ortega-Barria, Eduardo
    Colindres, Romulo
    Pircon, Jean-Yves
    DeAntonio, Rodrigo
    Van Dyke, Melissa K.
    MEDICINE, 2015, 94 (02) : e320
  • [10] Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France
    Robert Cohen
    Edouard Bingen
    Corinne Levy
    Franck Thollot
    Michel Boucherat
    Véronique Derkx
    Emmanuelle Varon
    BMC Infectious Diseases, 12